Romosozumab has no impact on radiographic or clinical outcomes following hip fracture ORIF
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip FracturesJ Bone Joint Surg Am.2020
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Hip fractures are one of the leading causes of disability worldwide, and continue to grow in numbers given the aging global population. When hip fractures are repaired with open reduction, internal fixation, there is concern about the bone quality and healing potential in this population. Thus, numerous different therapies have been investigated recently in an effort to promote bone healing in thi...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue